TABLE 3.
Incidence, severity, onset, and duration of CRS and NEs.
| TEAE | Cohort 4 (N = 41) |
|---|---|
| CRS | |
| Any, n (%) | 38 (93) |
| Worst grade 1, n (%) | 13 (32) |
| Worst grade 2, n (%) | 24 (59) |
| Worst grade 3, n (%) | 1 (2) |
| Worst grade 4, n (%) | 0 |
| Worst grade 5, n (%) | 0 |
| Median (range) time to onset of any grade CRS, days | 2·0 (1·0–8·0) |
| Median (range) duration, days | 6·5 (2·0–16·0) |
| NEs | |
| Any, n (%) | 25 (61) |
| Worst grade 1, n (%) | 14 (34) |
| Worst grade 2, n (%) | 4 (10) |
| Worst grade 3, n (%) | 7 (17) |
| Worst grade 4, n (%) | 0 |
| Worst grade 5, n (%) | 0 |
| Median (range) time to onset of any grade NE, days | 6·0 (1·0–93·0) |
| Median (range) duration, days | 8·0 (1·0–144·0) |
CRS, cytokine release syndrome; NE, neurologic event; TEAE, treatment‐emergent adverse event.